This company listing is no longer active
Indivior (2IVA) Stock Overview
Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
2IVA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Indivior PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£19.30 |
| 52 Week High | UK£78.00 |
| 52 Week Low | UK£14.50 |
| Beta | -0.031 |
| 1 Month Change | 11.56% |
| 3 Month Change | 24.52% |
| 1 Year Change | 19.88% |
| 3 Year Change | 297.12% |
| 5 Year Change | -9.81% |
| Change since IPO | 918.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2IVA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 0.5% |
| 1Y | 19.9% | 25.6% | 8.5% |
Return vs Industry: 2IVA exceeded the German Pharmaceuticals industry which returned -8.3% over the past year.
Return vs Market: 2IVA exceeded the German Market which returned 0.8% over the past year.
Price Volatility
| 2IVA volatility | |
|---|---|
| 2IVA Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 14.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 2IVA has not had significant price volatility in the past 3 months.
Volatility Over Time: 2IVA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1,000 | Mark Crossley | www.indivior.com |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company’s product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet.
Indivior PLC Fundamentals Summary
| 2IVA fundamental statistics | |
|---|---|
| Market cap | €2.80b |
| Earnings (TTM) | -€46.46m |
| Revenue (TTM) | €879.95m |
Is 2IVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2IVA income statement (TTM) | |
|---|---|
| Revenue | US$947.00m |
| Cost of Revenue | US$161.00m |
| Gross Profit | US$786.00m |
| Other Expenses | US$836.00m |
| Earnings | -US$50.00m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 83.00% |
| Net Profit Margin | -5.28% |
| Debt/Equity Ratio | 331.9% |
How did 2IVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/13 12:02 |
| End of Day Share Price | 2023/05/29 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indivior Pharmaceuticals, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Graham Glyn Parry | BofA Global Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Brandon Folkes | H.C. Wainwright & Co. |